Case Study: Ribbon Bio and Syngoi Technologies
A Seamless Pathway to Fully Synthetic Cell-Free DNA
Learn how Ribbon Bio and Syngoi created an end-to-end cell-free synthetic DNA workflow from research to manufacturing. Ribbon Bio’s NGS-verified MiroSynth™ DNA supplies a sequence-accurate foundation with regulatory elements built in; Syngoi’s xDNA™ platform then rapidly amplifies it from µg to gram-scale within weeks — fully synthetic and plasmid-free for safer therapeutic DNA.
Highlights
- Sequence-accurate start: NGS-verified MiroSynth™ DNA with promoters/enhancers for complex designs
- Therapeutic tailoring: Custom adaptors (10–100 nt) to modulate properties and safety
- Rapid scalability: µg input → gram-scale oDNA™ output in a cell-free workflow
- Plasmid-free & clean: No backbones, AR markers, endotoxin, or host DNA
- Built for the clinic: Global support and cGMP-aligned path from early research through manufacturing
Title
Learn how Ribbon Bio and Syngoi created an end-to-end cell-free synthetic DNA workflow from research to manufacturing. Ribbon Bio’s NGS-verified MiroSynth™ DNA supplies a sequence-accurate foundation with regulatory elements built in; Syngoi’s xDNA™ platform then rapidly amplifies it from µg to gram-scale within weeks — fully synthetic and plasmid-free for safer therapeutic DNA.
Highlights
- Sequence-accurate start: NGS-verified MiroSynth™ DNA with promoters/enhancers for complex designs
- Therapeutic tailoring: Custom adaptors (10–100 nt) to modulate properties and safety
- Rapid scalability: µg input → gram-scale oDNA™ output in a cell-free workflow
- Plasmid-free & clean: No backbones, AR markers, endotoxin, or host DNA
- Built for the clinic: Global support and cGMP-aligned path from early research through manufacturing